Lactams
Medchemexpress LLC Thalidomide-5-PEG2-Cl | 2230956-57-5 | 96.6% | 380.78 | 250 MG
Thalidomide-5-PEG2-Cl is a Thalidomide-based cereblon ligand that plays a crucial role in recruiting CRBN protein. It can be utilized to form PROTACs by linking to a target protein ligand. PROTACs are designed to selectively degrade target proteins within the intracellular ubiquitin-proteasome system by exploiting E3 ubiquitin ligase and target protein interactions.
- Thalidomide-based cereblon ligand
- Recruits CRBN protein
- Can be linked to form PROTACs
- Exploits ubiquitin-proteasome system
- Selectively degrades target proteins
Abcam (R,S)-Lenalidomide, Thalidomide analog, TNF alpha inhibitor, 100MG
MW 259.26 Da, Purity >98%. Thalidomide (ab120032) analog and TNF-α inhibitor. Potent antitumor and anti-inflammatory effects. Modulates and potentiates host immune responses against multiple myeloma. Active in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Medchemexpress LLC (S)-Thalidomide | 841-67-8 | MFCD00210219 | 99.52% | 258.23 | 50 MG
(S)-Thalidomide is the S-enantiomer of Thalidomide. It exhibits immunomodulatory, anti-inflammatory, antiangiogenic, and pro-apoptotic effects. (S)-Thalidomide induces teratogenic effects by binding to cereblon (CRBN).
- It is the S-enantiomer of thalidomide.
- It exhibits immunomodulatory effects.
- It has anti-inflammatory properties.
- It shows antiangiogenic effects.
- It possesses pro-apoptotic effects.
- It binds to cereblon (CRBN).
Medchemexpress LLC Thalidomide-4-OH | 5054-59-1 | MFCD03699892 | 99.9% | 274.23 g·mol⁻¹ | C13H10N2O5 | 10 G
Thalidomide-4-OH is a 4-hydroxylated metabolite of thalidomide used as a Cereblon (CRBN) ligand in chemical biology and PROTAC research. It is supplied as a high-purity solid for synthetic and biochemical applications, with recommended storage under inert atmosphere.
- High purity suitable for synthesis and assays.
- Molecular formula C13H10N2O5; molecular weight 274.23 g·mol⁻¹.
- Used as a CRBN ligand for recruitment of cereblon in PROTACs.
- Available in gram-scale quantities for research workflows.
- Solid with melting point 273-275 °C.
- Recommended storage: 4 °C under nitrogen; in solvent: -80 °C (6 months) or -20 °C (1 month).
Medchemexpress LLC Thalidomide-O-amido-PEG3-C2-NH2 TFA | 1957236-21-3 | 99.6% | 620.53 g/mol | C25H31F3N4O11 | 10 MG
Thalidomide-O-amido-PEG3-C2-NH2 TFA is a thalidomide-based cereblon ligand-linker conjugate (trifluoroacetic acid salt) designed as a building block for PROTAC synthesis. It links a thalidomide-derived E3 ligase ligand to a three-unit PEG spacer terminating in a C2 amino handle, enabling attachment to targeting ligands and facilitating cereblon-mediated target degradation.
- Thalidomide-based cereblon ligand for E3 ligase recruitment.
- Three-unit PEG linker providing flexible spacing and solubility.
- C2 amino terminal suitable for amide or urea coupling.
- Trifluoroacetic acid salt form for improved handling and stability.
- Molecular formula C25H31F3N4O11; molecular weight 620.53 g/mol.
- Soluble in DMSO at 50 mg/mL; ultrasonic may be required.
- Recommended storage: 4°C sealed; in solvent store at -80°C (6 months) or -20°C (1 month).
- Available in small research quantities suitable for synthesis, e.g., 10 mg.
Medchemexpress LLC Thalidomide-NH-C6-NH2 (hydrochloride) | 2375194-37-7 | 99.6% | 250 MG
Thalidomide-NH-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins. This product is for research use only.
- Synthesized E3 ligase ligand-linker conjugate
- Incorporates Thalidomide based cereblon ligand
- Used in PROTAC technology
- Exploits intracellular ubiquitin-proteasome system
- Selectively degrades target proteins
- For research use only
TARGETMOL CHEMICALS INC HKI-357 5MG
Also available in 1 mL, 1 mg, 10 mg, 25 mg, 50 mg, 100 mg and bulk. Please contact Fisher for quotes. HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 (IC50s 34 nM and 33 nM), effectively suppressing EGFR autophosphorylation (at Y1068), as well as AKT and MAPK phosphorylation. Purity 98.31%
Medchemexpress LLC Thalidomide-O-C6-azide | 2411389-65-4 | 99.1% | 399.40 | 50 MG
Thalidomide-O-C6-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates a thalidomide-based cereblon ligand and a linker used in PROTAC technology. This product is also a click chemistry reagent, containing an azide group that can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
- Synthesized E3 ligase ligand-linker conjugate
- Incorporates a thalidomide-based cereblon ligand
- Features a linker used in PROTAC technology
- Functions as a click chemistry reagent with an azide group
- Enables copper-catalyzed azide-alkyne cycloaddition reactions (CuAAc)
- Allows strain-promoted alkyne-azide cycloaddition (SPAAC) reactions
- Supports selective degradation of target proteins through PROTACs
Medchemexpress LLC Thalidomide-O-C6-azide | 2411389-65-4 | 99.1% | 399.40 | 100 MG
Thalidomide-O-C6-azide is a synthesized E3 ligase ligand-linker conjugate, incorporating the Thalidomide based cereblon ligand and a linker used in PROTAC technology. This click chemistry reagent contains an Azide group, enabling it to undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules or strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN groups. It is designed for research applications related to PROTACs, which utilize the ubiquitin-proteasome system to degrade target proteins.
- Incorporates cereblon ligand and a linker for PROTAC technology
- Click chemistry reagent with an Azide group
- Enables copper-catalyzed azide-alkyne cycloaddition (CuAAc)
- Facilitates strain-promoted alkyne-azide cycloaddition (SPAAC)
- Designed for research in protein degradation via PROTACs
Medchemexpress LLC Thalidomide-Piperazine 5-fluoride | 2222114-22-7 | 96.47% | 360.34 | 250 MG
Thalidomide-Piperazine 5-fluoride is a synthesized E3 ligase ligand-linker conjugate. It incorporates a cereblon ligand and a linker utilized in PROTAC technology, designed for research purposes.
- Synthesized E3 ligase ligand-linker conjugate
- Incorporates cereblon ligand
- Linker utilized in PROTAC technology
- Intended for research use only
- Purity: 96.47%
- Molecular weight: 360.34
- Solid appearance
- Color: Light yellow to green yellow
- Soluble in DMSO
Medchemexpress LLC Thalidomide-5-O-C9-NH2 hydrochloride | 451.94 | 5 MG
Thalidomide-5-O-C9-NH2 hydrochloride is a chemical compound primarily used as a laboratory chemical for research purposes and substance manufacturing. It is presented as a solid and is stable under recommended storage conditions.
- Solid appearance
- Stable under recommended storage conditions
- For research use only
Medchemexpress LLC Thalidomide-NH-PEG4-COOH | 2412056-48-3 | 96.7% | 521.52 | 50 MG
Thalidomide-NH-PEG4-COOH is an E3 ligase ligand-linker conjugate which can be used for synthesizing dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP.
- E3 ligase ligand-linker conjugate
- Used for synthesizing dCBP-1
- Potent and selective heterobifunctional degrader of p300/CBP
- Purity of 96.7%
- Appearance: yellow to green (solid-liquid mixture)
- Store at -20°C, protect from light
Medchemexpress LLC Thalidomide-O-amido-C4-NH2 trifluoroacetate | 1799711-25-3 | MFCD31560484 | 99.9% | 516.42 g/mol | C21H23F3N4O8 | 500 MG
Thalidomide-O-amido-C4-NH2 (TFA) is a thalidomide-derived cereblon ligand-linker conjugate supplied as the trifluoroacetate salt for use in PROTAC and degrader research. The material is provided as a white to off-white solid with documented purity, solubility, and storage recommendations to support formulation and biological testing.
- Thalidomide-based cereblon ligand-linker conjugate (TFA salt)
- High purity: 99.92% (LCMS)
- Molecular weight 516.42 g/mol; formula C21H23F3N4O8
- Solubility: DMSO 42.86 mg/mL; established in vivo vehicle protocols at ≥2.5 mg/mL
- Storage: solid at 4°C under nitrogen; in solution -80°C (up to 6 months) or -20°C (up to 1 month)
- Intended for use in synthesis and biological evaluation of PROTACs and E3 ligase degrader studies
Medchemexpress LLC Thalidomide-O-amido-PEG2-C2-NH2 (TFA) | 1957235-75-4 | 576.48 | 25 MG
Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide-based cereblon ligand and 2-unit PEG linker used in PROTAC technology. PROTACs contain two different ligands connected by a linker, one for an E3 ubiquitin ligase and the other for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
- E3 ligase ligand-linker conjugate
- Incorporates thalidomide-based cereblon ligand
- 2-unit PEG linker
- Used in PROTAC technology
- Exploits the intracellular ubiquitin-proteasome system
- Selectively degrades target proteins